Affitech AS, a Norway-based human antibody discovery and development company, has announced the completion of its fourth private placement, raising an additional 30 million Norwegian kroner ($4.5 million). The placement enables the company to continue its current course to push the discovery and development of human therapeutic antibody products and to further strengthen its proprietary technology platforms. The private placement included existing shareholders Teknoinvest, Ferd Venture and Four Seasons Venture, as well as the new investor Braganza AS.
Martin Welschof, chief executive of Affitech, says that "this is a major step forward towards reaching our strategic goals. This round of financing will support the expansion of our product pipeline and the extension of our combined approach towards antibody/target discovery."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze